… Parkinson disease (PD) has been heavily influenced by the dramatic response to dopamine
… First, substantial evidence now indicates that dopamine oxidation is unlikely to substantially …

… disease and altered striatal microvascularisation in PD. The interesting field of non-dopaminergic
drug therapy … improve drug therapy of parkinsonian symptoms, which do not respond to …

… experience in managing patients with the disease. Current drug therapy in Parkinson's
disease is symptomatic and primarily aimed at restoring dopaminergic function in the striatum. …

… of dopaminergic medications in each patient by means of a L-dopa equivalent daily dose
(LEDD, mg/day). This was calculated from the dosages of administered dopaminergic drugs …

… Parkinson's disease (PD) is a progressive extrapyramidal motor disorder. Pathologically, this
disease is characterized by the selective dopaminergic (DAergic) neuronal degeneration in …

… 23 showed the use of levodopa increased Unified Parkinson Disease Rating Scale (UPDRS)
scores by … in PD and the dopaminergic drugs used in treatment. Studies have shown that …

… A few Parkinson patients develop a disabling pattern of compulsive dopaminergic drug
use (“dopamine dysregulation syndrome”—DDS). DDS patients commonly identify aversive …

… R Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine
… AJ Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine …

… in a drug-… in drug-naive patients for dopaminergic challenge tests predicting a response to
chronic levodopa may be as high as 40%; therefore, acute challenge with dopaminergic drugs …

… with Parkinson's disease (PD), either untreated or under therapy with dopaminergic agents
(l-Dopa alone or l-dopa + dopamine … In addition, patients taking l-Dopa + dopamine agonists …